Phase Bioscience Raises $25 Million
Phase Bioscience Inc., a Durham, N.C.-based developer of therapeutic fusion proteins, has raised$25 million in new Series B funding. New Enterprise Associates and a unit of OSI Pharmaceuticals were joined by return backers Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures. The company previously raised around $6.8 million.
8 January 2010•3 mins read
